Controlled Release in Oral Drug Delivery

Controlled Release in Oral Drug Delivery?provides focus on specific topics, complementing other books in the initial CRS series. Each chapter?sets the context for the inventions described and describe the latitude that the inventions allow. In order to provide some similar look to each chapter, the coverage includes the historical overview, candidate drugs, factors influencing design and development, formulation and manufacturing and delivery system design. This volume?was written along three main sections: the relevant anatomy and physiology, a discussion on candidates for oral drug delivery and the major three groups of controlled release systems: diffusion control (swelling and inert matrices); environmental control (pH sensitive coatings, time control, enzymatic control, pressure control) and finally lipidic systems.

Clive Wilson is the J. P. Todd Professor of Pharmaceutics at Strathclyde University in Glasgow, Scotland and the current president of the European Union Federation for Pharmaceutical Sciences. He is the Chief Scientist of Bio-Images Research Group, a Phase II imaging specialist clinical unit in Glasgow Royal Infirmary.Major areas of research have been the study of the behaviour of drug formulations in man. With colleagues at Nottingham, he pioneered applications of scintigraphy in the study of physiological and patho-physiological effects of transit on drug absorption and began the investigations into regional drug absorption in man. This was later applied to the design and optimisation of oral dosage forms, in silico modelling of formulations in man and studies on IVIVR. He has published more than 150 papers, six books and over 130 reviews and book chapters. He was made a fellow of the Controlled Release Society in June 2010 and a Fellow of the Academy of Pharmaceutical Sciences in September 2010. Patrick Crowley has over 40 years’ experience in dosage form development in the pharmaceutical industry, in both the UK and USA. He has played key roles in the development of 16 commercial products, including fermentation products, semi synthetics, synthetic structures and a biopharmaceutical product and holds several formulation-related Patents. His interests and publications include drug and product stability, enhancing performance by dosage form design and the application of Quality by Design principles and practices in dosage form development, manufacture and control.